Ocular Therapeutix Gets Lead Product Back On Track
Executive Summary
The long-acting eye insert Dextenza has been accepted for review by the US FDA, a piece of good news for Ocular Therapeutix that had previously received a complete response letter on manufacturing issues and a mixed bag of late-stage clinical trial results.
You may also be interested in...
Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed
The latest drug development news and highlights from our US FDA Performance Tracker.
Does Ocular's Latest CRL Mean A Minor Delay For Dextenza, Or A New NDA?
The biotech sought a three-month action date extension with new manufacturing process data submitted to FDA just one day before the complete response letter.
Keeping Track: US FDA Shoots Down Lilly's Baricitinib, Approves Neurocrine's Ingrezza
The latest drug development news and highlights from our FDA Performance Tracker.